➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Baxter
McKesson
Mallinckrodt
Harvard Business School

Last Updated: September 24, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PEMIGATINIB

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Pemigatinib

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03656536 A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302) Not yet recruiting Incyte Corporation Phase 3 2018-11-01 The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement.
NCT03822117 Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations Not yet recruiting Incyte Corporation Phase 2 2019-05-17 The purpose of this study is to evaluate the efficacy and safety of pemigatinib in participants with previously treated locally advanced/metastatic or surgically unresectable solid tumor malignancies harboring activating FGFR mutations or translocations.
NCT03914794 A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors Not yet recruiting Incyte Corporation Phase 2 2019-05-01 This phase II trial studies how well Pemigatinib (an orally administered inhibitor of fibroblast growth factor receptors 1, 2, and 3) works in non-muscle invasive bladder cancer (NMIBC) patients with recurrent tumors and a prior history of low- or intermediate-risk NMIBC tumors. Participants will receive pemigatinib for 4-6 weeks prior to standard of care transurethral resection of bladder tumor (TURBT).
NCT03914794 A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors Not yet recruiting Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Phase 2 2019-05-01 This phase II trial studies how well Pemigatinib (an orally administered inhibitor of fibroblast growth factor receptors 1, 2, and 3) works in non-muscle invasive bladder cancer (NMIBC) patients with recurrent tumors and a prior history of low- or intermediate-risk NMIBC tumors. Participants will receive pemigatinib for 4-6 weeks prior to standard of care transurethral resection of bladder tumor (TURBT).
NCT04003610 Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205) Not yet recruiting Incyte Corporation Phase 2 2019-10-15 The purpose of this study is to evaluate the safety and efficacy of pemigatinib plus pembrolizumab or pemigatinib alone versus the standard of care for participants with metastatic or unresectable urothelial carcinoma who are not eligible to receive cisplatin, are harboring FGFR3 mutation or rearrangement, and who have not received prior treatment.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Pemigatinib

Condition Name

Condition Name for Pemigatinib
Intervention Trials
Unresectable Cholangiocarcinoma 2
Metastatic Cholangiocarcinoma 2
Solid Tumor Malignancy 1
FGFR3 Gene Translocation 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Pemigatinib
Intervention Trials
Neoplasms 3
Cholangiocarcinoma 3
Carcinoma 2
Carcinoma, Transitional Cell 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Pemigatinib

Trials by Country

Trials by Country for Pemigatinib
Location Trials
United States 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Pemigatinib
Location Trials
Wisconsin 2
Tennessee 1
North Carolina 1
Missouri 1
Illinois 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Pemigatinib

Clinical Trial Phase

Clinical Trial Phase for Pemigatinib
Clinical Trial Phase Trials
Phase 3 1
Phase 2 8
Phase 1 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Pemigatinib
Clinical Trial Phase Trials
Not yet recruiting 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Pemigatinib

Sponsor Name

Sponsor Name for Pemigatinib
Sponsor Trials
Incyte Corporation 6
Innovent Biologics (Suzhou) Co. Ltd. 2
Academic and Community Cancer Research United 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Pemigatinib
Sponsor Trials
Industry 10
Other 7
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
Medtronic
Harvard Business School
Mallinckrodt
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.